SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
SAREPTA THERAPEUTICS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Increase in other assets → operating reconciliation: $82,387,000.00Increase in inventory → operating reconciliation: $39,911,000.00Decrease in manufacturing-related deposits and prepaids → operating reconciliation: $25,792,000.00Stock-based compensation → operating reconciliation: $24,472,000.00(Decrease) increase in accrued expenses → operating reconciliation: $22,695,000.00Decrease (increase) in accounts receivable → operating reconciliation: $17,993,000.00Non-cash inventory write-downs for obsolescence → operating reconciliation: $11,599,000.00Depreciation and amortization → operating reconciliation: $10,409,000.00Non-cash interest expense → operating reconciliation: $9,394,000.00(Decrease) increase in lease liabilities and other liabilities → operating reconciliation: $6,084,000.00Reduction in the carrying amounts of the right of use assets → operating reconciliation: $3,212,000.00Loss on strategic investments → operating reconciliation: $448,000.00operating reconciliation → Net cash from operating activities: $197,070,000.00operating reconciliation → Net income (loss): $4,890,000.00operating reconciliation → Decrease in deferred revenue: $32,127,000.00operating reconciliation → Decrease in accounts payable: $19,394,000.00operating reconciliation → Accretion of investment discount, net: $905,000.00operating reconciliation → Other: $10,000.00Proceeds from borrowings under the Revolving Credit Facility → financing reconciliation: $175,000,000.00financing reconciliation → Repayments of borrowings under the Revolving Credit Facility: $175,000,000.00Net cash used in investing activities → investing reconciliation: $93,372,000.00Maturity and sales of available-for-sale securities → investing reconciliation: $88,031,000.00investing reconciliation → Remaining investing cash flows, net (calculated): $180,848,000.00investing reconciliation → Purchase of property and equipment: $555,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $477,575,000.00Net cash from operating activities → Cash sources and uses: $197,070,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $581,273,000.00Cash sources and uses → Net cash used in investing activities: $93,372,000.00Net income (loss): -$4,890,000.00Net income (loss)−$4.89 MLoss on strategic investments: $448,000.00Investment gain & loss+$448.00 KStock-based compensation: $24,472,000.00Stock-based compensation+$24.47 MDepreciation and amortization: $10,409,000.00Depreciation & amortization+$10.41 MNon-cash inventory write-downs for obsolescence: $11,599,000.00Inventory write-downs+$11.60 MNon-cash interest expense: $9,394,000.00Non-cash interest expense+$9.39 MReduction in the carrying amounts of the right of use assets: $3,212,000.00Right-of-use assets+$3.21 MAccretion of investment discount, net: -$905,000.00Discount accretion, net−$905.00 KOther: -$10,000.00Other non-cash items−$10.00 KDecrease (increase) in accounts receivable: $17,993,000.00Accounts receivable+$17.99 MDecrease in manufacturing-related deposits and prepaids: $25,792,000.00Manufacturing deposits & prepaids+$25.79 MIncrease in inventory: $39,911,000.00Inventories+$39.91 MIncrease in other assets: $82,387,000.00Other operating assets+$82.39 MDecrease in deferred revenue: -$32,127,000.00Unearned revenue−$32.13 MDecrease in accounts payable: -$19,394,000.00Accounts payable−$19.39 M(Decrease) increase in accrued expenses: $22,695,000.00Accrued liabilities+$22.70 M(Decrease) increase in lease liabilities and other liabilities: $6,084,000.00Accrued & other liabilities+$6.08 MNet cash from operating activities: $197,070,000.00Operating cash+$197.07 Moperating reconciliation: $254,396,000.00Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program: $0.00Proceeds from borrowings under the Revolving Credit Facility: $175,000,000.00Credit line borrowings+$175.00 MRepurchases of common stock: $0.00Repayments of borrowings under the Revolving Credit Facility: -$175,000,000.00Credit line repayments−$175.00 MPayments related to obtaining Revolving Credit Facility: $0.00Net cash from financing activities: $0.00Financing cash$0.00financing reconciliation: $175,000,000.00Purchase of property and equipment: -$555,000.00PP&E purchases−$555.00 KMaturity and sales of available-for-sale securities: $88,031,000.00AFS securities proceeds+$88.03 MPurchase of intangible assets: -$0.00Acquisition of strategic investments: $0.00Remaining investing cash flows, net (calculated): -$180,848,000.00Remaining investing (calculated)−$180.85 MNet cash used in investing activities: -$93,372,000.00. Cash required to fund net payments.Investing cash−$93.37 Minvesting reconciliation: $181,403,000.00Cash sources and uses: $674,645,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $477,575,000.00Beginning cash$477.58 MEnding cash: Cash, cash equivalents, and restricted cash: $581,273,000.00Ending cash$581.27 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsNet loss −$4.89M + net operating adjustments $201.96M = operating cash +$197.07MFree cash flow$196.52 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$103.70 MEnding cash − beginning cash
Chart details

SAREPTA THERAPEUTICS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
477,575,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
197,070,000 US dollars. Net cash provided.
Net income (loss)
negative 4,890,000 US dollars
Loss on strategic investments
448,000 US dollars
Stock-based compensation
24,472,000 US dollars
Depreciation and amortization
10,409,000 US dollars
Non-cash inventory write-downs for obsolescence
11,599,000 US dollars
Non-cash interest expense
9,394,000 US dollars
Reduction in the carrying amounts of the right of use assets
3,212,000 US dollars
Accretion of investment discount, net
negative 905,000 US dollars
Other
negative 10,000 US dollars
Decrease (increase) in accounts receivable
17,993,000 US dollars
Decrease in manufacturing-related deposits and prepaids
25,792,000 US dollars
Increase in inventory
39,911,000 US dollars
Increase in other assets
82,387,000 US dollars
Decrease in deferred revenue
negative 32,127,000 US dollars
Decrease in accounts payable
negative 19,394,000 US dollars
(Decrease) increase in accrued expenses
22,695,000 US dollars
(Decrease) increase in lease liabilities and other liabilities
6,084,000 US dollars
Investing activities
negative 93,372,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the investing total. This quarter is the year to date less the prior quarter's year to date. The prior quarter reported part of this section under different lines (Purchase of available-for-sale securities), so Purchase of investments cannot be separated for this quarter. It may combine inflows and outflows.
Purchase of property and equipment
negative 555,000 US dollars
Maturity and sales of available-for-sale securities
88,031,000 US dollars
Purchase of intangible assets
0 US dollars
Acquisition of strategic investments
0 US dollars
Remaining investing cash flows, net (calculated)
negative 180,848,000 US dollars
Financing activities
0 US dollars. No net cash provided or used.
Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program
0 US dollars
Proceeds from borrowings under the Revolving Credit Facility
175,000,000 US dollars
Repurchases of common stock
0 US dollars
Repayments of borrowings under the Revolving Credit Facility
negative 175,000,000 US dollars
Payments related to obtaining Revolving Credit Facility
0 US dollars
Operating adjustment reconciliation
254,396,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
175,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing displayed reconciliation
181,403,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
581,273,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
674,645,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
103,698,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
197,070,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
555,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
196,515,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$4.89M + net operating adjustments $201.96M = operating cash +$197.07M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 197,070,000 US dollars minus 555,000 US dollars equals 196,515,000 US dollars.
SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!